Nureca Past Earnings Performance
Past criteria checks 1/6
Nureca's earnings have been declining at an average annual rate of -34.3%, while the Medical Equipment industry saw earnings growing at 21.3% annually. Revenues have been declining at an average rate of 4% per year. Nureca's return on equity is 0.4%, and it has net margins of 0.9%.
Key information
-34.3%
Earnings growth rate
-37.1%
EPS growth rate
| Medical Equipment Industry Growth | 23.0% |
| Revenue growth rate | -4.0% |
| Return on equity | 0.4% |
| Net Margin | 0.9% |
| Next Earnings Update | 15 May 2024 |
Revenue & Expenses BreakdownBeta
How Nureca makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 962 | 8 | 165 | 0 |
| 30 Sep 23 | 1,016 | 10 | 173 | 0 |
| 30 Jun 23 | 1,070 | -48 | 192 | 0 |
| 31 Mar 23 | 1,113 | -82 | 207 | 0 |
| 31 Dec 22 | 1,311 | -81 | 287 | 0 |
| 30 Sep 22 | 1,514 | -37 | 268 | 0 |
| 30 Jun 22 | 1,616 | 46 | 117 | 0 |
| 31 Mar 22 | 2,555 | 450 | 223 | 0 |
| 31 Dec 21 | 2,602 | 515 | 114 | 0 |
| 30 Sep 21 | 2,577 | 518 | 181 | 0 |
| 30 Jun 21 | 3,027 | 731 | 66 | 0 |
| 31 Mar 21 | 2,135 | 464 | 144 | 0 |
| 31 Mar 20 | 994 | 64 | 65 | 0 |
| 31 Mar 19 | 619 | 62 | 34 | 0 |
| 31 Mar 18 | 201 | 31 | 6 | 0 |
| 31 Mar 17 | 0 | 0 | 0 | 0 |
Quality Earnings: NURECA has a large one-off gain of ₹24.4M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: NURECA became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NURECA's earnings have declined by 34.3% per year over the past 5 years.
Accelerating Growth: NURECA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: NURECA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (42.4%).
Return on Equity
High ROE: NURECA's Return on Equity (0.4%) is considered low.